Acumen presents first clinical, biomarker data for ACU193

Acumen Pharmaceuticals will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug in early AD during an Emerging Science Session at the American Academy of Neurology 2024 Annual Meeting in Denver on April 16, 2024. The results build upon Acumen’s prior presentations at the AD/PD 2024 Annual Meeting and positive topline data first announced in July 2023 and will be presented together for the first time with expanded analysis. “For the first time, we’re presenting a comprehensive set of safety, biomarker and target engagement data from INTERCEPT-AD, which continue to support sabirnetug’s mechanism and potential to offer differentiated safety and efficacy as a next-generation treatment for people with early Alzheimer’s disease,” said Eric Siemers, M.D., Chief Medical Officer of Acumen and presenting author. “The results of this robust Phase 1 trial give us hope that sabirnetug could have a safety and efficacy profile that could make it an attractive option for a large number of patients. We look forward to applying insights learned from INTERCEPT-AD as we embark upon our ALTITUDE-AD Phase 2 trial for sabirnetug.”